BreakingNews

Category archive

lawsuits

Family Fights to Stop Hewlett Packard and Insurer From Cutting Off Healthcare that Saves Father’s Life, According to Federal Lawsuit by Jonathan Davidson Law Firm

Reading Time: 2 minutes

RIVERSIDE, Calif., March 30, 2017 /360WiseNews/ — According to a lawsuit filed in the federal District Court in the Northern District of California in San Jose, the experience of one patient, Jonathan Davidson, puts a spotlight on the large companies Hewlett Packard Enterprise and United HealthCare seeking to manipulate healthcare payment systems by cutting off a patient’s life-saving care, as alleged in the lawsuit in which Mr. Davidson’s Jonathan Davidson Law Firm is representing him. Hewlett Packard Enterprise (HP) plans a merger this week with another giant computer services company, Computer Sciences Corporation, which has repeatedly been charged with systematically engaging in false or fraudulent practices in its business with Medicaid, the British National Health Service and others. In the merger, 120,000 or so HP employees are set to be “spun off” into a newly created HP-CSC merger company called “DXC Technology,” with their prior HP sponsored health plan replaced by a “private exchange model” adopted for its “lower cost structure” for HP.

According to Jonathan Davidson, his case exemplifies the abuses that victimize millions of ill patients, including employees and others with company or group medical coverage, and also the public and taxpayers through inflated medical and health insurance costs. Keep Reading

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Seacor Holdings Inc. (CKH)

Reading Time: 1 minute

NEW YORK, March 2, 2017 /360WiseNews/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Seacor Holdings Inc. (“Seacor” or the “Company”) (NYSE: CKH). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/ckh.

The investigation concerns whether Seacor and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On March 2, 2017, pre-market, Seacor filed to postpone its 2016 annual report, expressing that the it has not completed an assessment of its internal controls over financial reporting due to certain control deficiencies. Seacor said that the deficiencies related to impairment determinations and could represent material weaknesses.  Following this news, Seacor stock dropped as much as $4.84, or 6.76%, during intraday trading on March 2, 2017. Keep Reading

Dillard’s Recalls Baby Jackets Due to Choking Hazard

Reading Time: 2 minutes

WASHINGTON, Feb. 28, 2017 /360WiseNews/ —

Recall Summary

 The U.S. Consumer Product Safety Commission is an independent federal agency created by Congress in 1973 and charged with protecting the American public from unreasonable risks of serious injury or death from more than 15,000 types of consumer products under the agency's jurisdiction. To report a dangerous product or a product-related injury, call the CPSC hotline at 1-800-638-2772, or visit http://www.saferproducts.gov. Further recall information is available at http://www.cpsc.gov.

Name of Product: Faux-Fur Hooded Bear Coats

Hazard: The metal snaps on the jackets can detach, posing a choking hazard to children.

Remedy: Refund

Consumers should immediately stop using the recalled coat and return it to the nearest Dillard’s store for a full refund. To obtain a prepaid envelope to return the product by mail, customers can contact Dillard’s.

Consumer Contact: Dillard’s at 800-345-5273 from 8 a.m. to 1 a.m. ET Monday through Saturday and 10 a.m. to 8 p.m. ET Sunday, by email at [email protected] or online at www.dillards.com and click on “Product Recalls” at the bottom of the page for more information.

Recall Details

Units: About 1,800

Description: This recall involves the Starting Out Baby Girls 3-24 Months Faux-Fur Hooded Bear Coat with style numbers F64CI801I and F64CI801N. The coat is labeled for children aged 3-24 months and has metal snap closures. It is an ivory faux fur coat with animal ears on the hood. The “Starting Out” logo and style number can be found on the tag sewn into the garment.

Incidents/Injuries: Dillard’s has received one report of snaps detaching. No injuries have been reported.

Sold at: Dillard’s stores nationwide and online at www.dillards.com from September 2016 through December 2016 for about $40.

Importer/Distributor: Dillard’s Inc., of Little Rock, Ark.

Manufactured in: China

About U.S. CPSC:
The U.S. Consumer Product Safety Commission is charged with protecting the public from unreasonable risks of injury or death associated with the use of thousands of types of consumer products under the agency’s jurisdiction.  Deaths, injuries, and property damage from consumer product incidents cost the nation more than $1 trillion annually. CPSC is committed to protecting consumers and families from products that pose a fire, electrical, chemical or mechanical hazard. CPSC’s work to ensure the safety of consumer products – such as toys, cribs, power tools, cigarette lighters and household chemicals – contributed to a decline in the rate of deaths and injuries associated with consumer products over the past 40 years. Keep Reading

SGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017

Reading Time: 2 minutes

NEW YORK, Feb. 22, 2017 /360WiseNews/ — The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc. (NASDAQ: SGEN) securities between October 27, 2016 and December 23, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/seattle-genetics-inc. There is no cost or obligation to you.

According to the complaint, throughout the class period, Seattle Genetics made false and/or misleading statements and/or failed to disclose that: (a) its product in development, vadastuximab talirine, presents a significant risk of fatal hepatoxicity; (b) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia; and (c) as a result, the Company’s statements were materially false and misleading at all relevant times.

On December 27, 2016, Seattle Genetics issued a press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine. Keep Reading

Go to Top